CanSino Biologics Inc (CJH) - Net Assets

Latest as of June 2025: €4.90 Billion EUR ≈ $5.73 Billion USD

Based on the latest financial reports, CanSino Biologics Inc (CJH) has net assets worth €4.90 Billion EUR (≈ $5.73 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€7.71 Billion ≈ $9.01 Billion USD) and total liabilities (€2.80 Billion ≈ $3.28 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CanSino Biologics Inc (CJH) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets €4.90 Billion
% of Total Assets 63.64%
Annual Growth Rate 47.9%
5-Year Change -19.12%
10-Year Change N/A
Growth Volatility 120.74

CanSino Biologics Inc - Net Assets Trend (2016–2024)

This chart illustrates how CanSino Biologics Inc's net assets have evolved over time, based on quarterly financial data. Also explore CJH asset base for the complete picture of this company's asset base.

Annual Net Assets for CanSino Biologics Inc (2016–2024)

The table below shows the annual net assets of CanSino Biologics Inc from 2016 to 2024. For live valuation and market cap data, see CJH market cap overview.

Year Net Assets Change
2024-12-31 €4.91 Billion
≈ $5.74 Billion		 -7.14%
2023-12-31 €5.29 Billion
≈ $6.18 Billion		 -27.03%
2022-12-31 €7.25 Billion
≈ $8.47 Billion		 -15.24%
2021-12-31 €8.55 Billion
≈ $9.99 Billion		 +40.80%
2020-12-31 €6.07 Billion
≈ $7.10 Billion		 +312.84%
2019-12-31 €1.47 Billion
≈ $1.72 Billion		 +192.75%
2018-12-31 €502.32 Million
≈ $587.26 Million		 -17.29%
2017-12-31 €607.33 Million
≈ $710.03 Million		 +183.17%
2016-12-31 €214.47 Million
≈ $250.74 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to CanSino Biologics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 180121300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Other Components €6.85 Billion 139.46%
Total Equity €4.91 Billion 100.00%

CanSino Biologics Inc Competitors by Market Cap

The table below lists competitors of CanSino Biologics Inc ranked by their market capitalization.

Company Market Cap
Zhejiang Wandekai Fluid Equipment Technology Co. Ltd. A
SHE:301309
 $493.27 Million
PostNL NV
AS:PNL
 $493.42 Million
Vinte Viviendas Integrales S.A.B. de C.V
MX:VINTE
 $493.92 Million
Jiangsu Newamstar Packaging Machinery Co Ltd
SHE:300509
 $494.01 Million
Johnson Outdoors Inc
NASDAQ:JOUT
 $493.23 Million
Hollyland China Electronics Technology Corp Ltd
SHE:002729
 $493.18 Million
First Trust High Yield Opportunities 2027 Term Fund
NYSE:FTHY
 $493.13 Million
Ventec International Group Co Ltd
TW:6672
 $492.88 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in CanSino Biologics Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 5,274,604,000 to 4,909,872,000, a change of -364,732,000 (-6.9%).
  • Net loss of 378,884,000 reduced equity.
  • Share repurchases of 6,962,000 reduced equity.
  • New share issuances of 7,032,000 increased equity.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income €-378.88 Million -7.72%
Share Repurchases €6.96 Million -0.14%
Share Issuances €7.03 Million +0.14%
Other Changes €14.08 Million +0.29%
Total Change €- -6.91%

Book Value vs Market Value Analysis

This analysis compares CanSino Biologics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.16x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 1.14x to 0.16x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 €2.78 €3.18 x
2018-12-31 €2.30 €3.18 x
2019-12-31 €6.60 €3.18 x
2020-12-31 €24.53 €3.18 x
2021-12-31 €32.31 €3.18 x
2022-12-31 €27.27 €3.18 x
2023-12-31 €21.32 €3.18 x
2024-12-31 €19.84 €3.18 x

Capital Efficiency Dashboard

This dashboard shows how efficiently CanSino Biologics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -7.72%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -45.93%
  • • Asset Turnover: 0.10x
  • • Equity Multiplier: 1.62x
  • Recent ROE (-7.72%) is above the historical average (-11.55%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2016 -23.24% 0.00% 0.00x 1.52x €-71.30 Million
2017 -10.61% -34434.67% 0.00x 1.43x €-125.18 Million
2018 -27.53% -12215.64% 0.00x 1.58x €-188.51 Million
2019 -10.66% -6865.49% 0.00x 1.21x €-303.82 Million
2020 -6.53% -2138.90% 0.00x 1.11x €-1.00 Billion
2021 23.94% 44.52% 0.36x 1.49x €1.11 Billion
2022 -13.48% -88.21% 0.09x 1.70x €-1.58 Billion
2023 -28.11% -429.55% 0.04x 1.77x €-2.01 Billion
2024 -7.72% -45.93% 0.10x 1.62x €-869.87 Million

Industry Comparison

This section compares CanSino Biologics Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $778,651,241
  • Average return on equity (ROE) among peers: -82.08%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
CanSino Biologics Inc (CJH) €4.90 Billion -23.24% 0.57x $493.24 Million
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) $6.51 Billion 11.81% 0.39x $635.99 Million
AYURCANN HOLDINGS CORP. (3ZQ0) $534.88K -741.80% 26.77x $113.81K
LORDS CO. WORLDW. HOLD. (4XM) $-1.01 Million 0.00% 0.00x $134.78K
EQL PHARMA AB (7JK) $154.75 Million 19.98% 0.85x $148.83 Million
Alkermes plc (8AK) $1.07 Billion 1.94% 0.48x $5.00 Billion
OPTIMI HEALTH CORP. (8BN) $9.58 Million -63.03% 0.52x $17.99 Million
LABIANA HEALTH S.A.EO-10 (8RK) $2.57 Million 9.87% 19.25x $40.60 Million
CANNABIS POLAND AB ZY-10 (8TE) $3.54 Million -57.78% 0.18x $1.75 Million
Apontis Pharma AG (APPH) $40.71 Million -1.83% 0.33x $91.63 Million
CRAFTPORT CANNABIS CORP. (BBW0) $-3.18 Million 0.00% 0.00x $1.45 Million

About CanSino Biologics Inc

F:CJH Germany Drug Manufacturers - Specialty & Generic
Market Cap
$493.24 Million
€421.89 Million EUR
Market Cap Rank
#12607 Global
#1337 in Germany
Share Price
€3.18
Change (1 day)
-0.63%
52-Week Range
€3.18 - €5.95
All Time High
€45.99
Categories
Companies in Germany Drug Manufacturers - Specialty & Generic
About

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are i… Read more